The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel. The objective of the open-label extension is to evaluate the extended safety and skin-irritation profile of topically administered oxybutynin gel.

The hypothesis is that topically administered oxybutynin gel will decrease (compared to placebo) the number of incontinence episodes per week, average daily urinary frequency, and urinary urgency; increase average urinary void volume; and improve patient quality of life.

• Urge Urinary Incontinence
• Urinary Frequency

• Drug: Oxybutynin
  Oxybutynin Gel
• Drug: Placebo
  Placebo Gel

• Oxybutynin Gel 56 mg/day: Experimental
  Intervention: Drug: Oxybutynin
• Oxybutynin Gel 84 mg/day: Experimental
  Intervention: Drug: Oxybutynin
• Placebo Gel: Placebo Comparator
  Intervention: Drug: Placebo

Inclusion Criteria:

• OAB symptoms of urge and/or mixed UI with a predominance of urge incontinence for at least 3 months
• Have a history of at least 1 - 2 urge episodes and 8 or more voids per day

Exclusion Criteria:

• Incontinence that is predominantly stress, insensate, or overflow in nature, or incontinence related to chronic illness, anatomical weakness/abnormalities or concomitant medications
• PVR volume > 200 mL or relative PVR > 50% of pre-void volume as determined by bladder ultrasound
• History of urinary retention, gastric retention, or uncontrollable narrow-angle glaucoma, or patients who are at risk for these conditions